{{val.symbol}}
{{val.value}}

Stocks signals & trading forecasts

IndexaCo Signals Marketplace - trading signals with real-time results on the financial markets from professional traders

Blogs

British regulator launches investigation into cloud business of Amazon, Google and Microsoft
Alphabet, stock, Microsoft, stock, Amazon, stock, British regulator launches investigation into cloud business of Amazon, Google and Microsoft The British regulator has launched an investigation into the dominance of technology titans Amazon, Microsoft and Google in the field of cloud services. The watchdog will assess how well the market is performing and will also examine barriers to new entrants in the sector.According to Ofcom, Amazon Web Service (AWS), Microsoft Azure and Google, called "hyperscalers" because of the size of the data centers used to process and store data, share about 81 percent of revenue in the U.K. cloud market.The investigation, which will last up to 12 months, seeks to "ensure that digital communication markets work well for people and businesses in the U.K.," the regulator said in a statement. It will work closely with the Competition and Markets Authority (CMA) and intends to consult on interim findings and publish a final report within a year.If competition is found to be disturbed and that companies and consumers are affected, Ofcom can take enforcement action, recommend regulatory or policy changes to the government, or refer the matter to the CMA for further investigation.Ofcom also plans to launch a broader investigation into messaging services and devices for accessing audio-visual content, including WhatsApp, FaceTime and Zoom, to see how they affect traditional telecommunications services such as calls and messages.The use of cloud services has increased dramatically in recent years. In 2018, less than 10 percent of all global enterprise IT spending was on public cloud services, but that figure rose to 17 percent last year as more people worked from home due to the pandemic. According to Ofcom, some experts expect that amount to reach 45% of enterprise IT spending by ...
Avatar
Read
Ford shares fall 4% on inflation expectations
Ford Motor, stock, Ford shares fall 4% on inflation expectations Automaker Ford Motor reported that supplier costs will rise about $1 billion more than expected in the current quarter because of inflation, and the company estimates it will have 40,000 to 45,000 vehicles in inventory without parts, delaying sales.Ford shares fell 4.42% to $14.27 at the Sept. 19 postmarket on the NYSE.The No. 2 automaker in the U.S. reiterated expectations for full-year 2022 adjusted earnings before interest and taxes of $11.5 billion to $12.5 billion.Ford said in July that its second-quarter results were driven by higher-margin vehicles, partly offset by higher commodity costs and expenses. At the time, Ford said it expected commodity costs to rise by $4 billion over the year, and added that management was "actively looking" for ways to offset rising costs.In July, Ford said it was facing continued supply chain disruptions.Over the past two years, automakers have faced a series of supply chain problems that have repeatedly delayed vehicle production, often due to a shortage of semiconductor ...
Avatar
Read
Microsoft's deal to buy Activision may not take place
Activision Blizzard, stock, Microsoft, stock, Microsoft\'s deal to buy Activision may not take place The U.K. plans to launch a thorough antitrust review (MSFT) and (ATVI). The Competition and Markets Authority has asked Microsoft to make concessions: to give competitors access to Activision Blizzard's most popular games. But the company refused.Recall that at the beginning of the year Microsoft announced plans to buy Activision Blizzard for $95 per share. Now the securities of the video game maker are trading at $76.55. That is, in theory, an increase of 25% is possible.Are the regulator's actions justified? Analysts believe that the British antitrust regulator's crackdown on Microsoft is justified. If Microsoft eats Activision, there will be less competition in three segments: gaming consoles, cloud gaming and subscription services.Especially since there's already an example. Last year, Microsoft acquired Bethesda Studios. Now this studio's releases have been canceled by its competitors. If history repeats itself with Activision, releases of its popular franchises on Sony game consoles could be canceled. Microsoft will dominate the market.How would the companies' stocks react? It's not certain that the British regulator's ban will definitely cancel the takeover, but the likelihood of a deal being derailed is increasing.For Activision stock, nothing will change globally if the deal happens or is canceled. It will have a much bigger impact on (SONY) stock, which could fall 7-9% if the purchase is approved. For Microsoft, the purchase of Activision will be seen as a positive 3-4% growth in shares. The company will get exclusive rights to game franchises, which will lead to an increase in sales of technology giant Bill ...
Avatar
Read
FedEx shares lost more than 16% after the withdrawal of its outlook for the year
FedEx, stock, FedEx shares lost more than 16% after the withdrawal of its outlook for the year FedEx Corp. withdrew its financial outlook for the year, issued three months ago, saying the slowdown in global demand accelerated in late August and will worsen.Shares of the issuer fell 16.58% on the NYSE postmarket Sept. 15 after reporting financial results that fell short of Wall Street targets. Slowing economic activity around the world reduced FedEx Express revenue by $500 million and FedEx Ground revenue by $300 million for the quarter, FedEx said.FedEx said it is cutting costs, including closing some offices, reducing hours and consolidating some sorting ...
Avatar
Read

Articles about financial markets

You can pay with cryptocurrency: which companies accept crypto in 2022
Ethereum/USD, cryptocurrency, Bitcoin/USD, cryptocurrency, Visa, stock, MasterCard, stock, Coca-Cola, stock, PayPal, stock, Shopify, stock, You can pay with cryptocurrency: which companies accept crypto in 2022 The governor of the Bank of England, Andrew Bailey, said that bitcoin is impractical as a means of payment. While cryptocurrencies are not being calculated massively. But today, large companies not only use blockchain, but also accept crypto as payment:Coca-Cola. In 2020, the corporation's Asia-Pacific division announced that it would allow customers in Australia and New Zealand to buy drinks with bitcoin and other coins. Payment is available through devices that accept digital payments.PayPal is the first payment system to add cryptocurrency for transactions. The company acts as an intermediary: the service will exchange cryptocurrency for ordinary dollars at the internal exchange rate, which already includes the cost of conversion.Visa and Mastercard, following PayPal, thought about the possibility of conducting transactions with cryptocurrencies. The systems focus on stablecoins, which have collateral in the form of real assets.Shopify is a platform for creating online stores. Thanks to the developers, the owners of these stores can accept cryptocurrency.Emirates. The airline from the UAE intends to accept bitcoins as payment. Moreover, Emirates will add its own NFT tokens to the site. This is not the first airline operating with cryptocurrencies. Latvian airBaltic has been selling tickets for the crypt for several years.Balenciaga, Gucci, Tag Heuer are also starting to accept cryptocurrency. Moreover, the new payment method will be available not only online, but also in regular stores using QR codes. And the first major retailer that started accepting the crypt was Overstock.Brazilian developer Gafisa announced that now an apartment can be bought for bitcoins. So the company wants to attract investors from other countries, and the cryptocurrency helps to transfer funds quickly and ...
Read
The US-Russian sanctions war: what threatens the semiconductor market?
Intel, stock, The US-Russian sanctions war: what threatens the semiconductor market? Against the background of geopolitical tensions around Ukraine, the US and Russian authorities are considering plans for possible sanctions against each other. Reuters previously reported that the White House is thinking about a complete ban on exports to Russia of semiconductors manufactured using American technologies. Such a ban may be imposed in the event of an invasion of Ukraine by the Russian Federation.At the same time, the Biden administration warned semiconductor manufacturers: they may face a shortage of the main components for the production of chips, namely C4F6 gas, neon and palladium.Neon is used to produce lasers that are used in microchips. Palladium is used in sensors and memory chips. And all this is largely supplied to the USA from Russia.According to the Techcet research group, neon is a byproduct of Russian steel production. Then it is exported to Ukraine, where it is additionally cleaned, and from there it is sent to the USA. If we talk about specific figures, 35% of palladium supplied to the USA is produced in Russia, and Ukraine accounts for more than 90% of neon supplies to the USA. If the United States restricts the import of semiconductors, Russia in response to this may restrict the import of raw materials for their production.What is the result?If the United States implements such a scenario, then prices for all electronics, in particular smartphones, laptops and PCs, will increase significantly. At the same time, if Russia restricts the supply of palladium and neon, the global shortage of semiconductors that we are currently seeing will only worsen. Market participants expect that in such a scenario, supply chains will not completely stop, but prices and the shortage of components will increase significantly.Against the background of all the news, some chip manufacturers have already begun to revise their supply chains in order to replace imports from Russia with more reliable suppliers. Although Intel (INTC), one of the largest processor manufacturers, said that it does not expect any influence of geopolitics on neon supplies.Opinion of analystsAll of the above is still guesswork and analysis of possible scenarios that can only be realized in the worst case. Most likely, all this will remain at the discussion stage, since an invasion scenario is unlikely.Despite this, a number of changes may occur in the semiconductor industry at the moment. Manufacturers will review their supply chains, which may harm Russian export companies, in particular, Norilsk Nickel (GMKN).Also, due to the alarming news, the prices of neon and palladium can fluctuate greatly. For example, in the early spring of 2014, against the background of unrest in Ukraine, neon prices increased by 600% at the moment. If this growth is repeated, the costs of semiconductor manufacturers may increase, which will worsen the shortage of ...
Read
The main trends of pharmaceutical corporations in 2022
JPMorgan Chase, stock, Pfizer, stock, Moderna, stock, The main trends of pharmaceutical corporations in 2022 The JPMorgan Chase & Co (JPM) annual healthcare conference ended in San Francisco on January 13. This event with a forty-year history is considered one of the most significant in the medical community: pharmaceutical company executives participate in it, important statements about mergers and acquisitions are made on its site, new drugs are presented and breakthrough research is announced.Taking into account the new realities, for the second year in a row, the event is held in an online format. Let's list the most interesting industry trends that were outlined in the speakers' speeches.The use of RNA is recognized as the main trend in pharmacologyRibonucleic acid (RNA) is one of the three main macromolecules in the cells of all living organisms. Although the functions of RNA are not yet fully understood, studies show that this acid plays an important role in the coding and regulation of genes.Ribonucleic acid has attracted increased attention in connection with the development of vaccines against Covid-19. The previous generation of vaccines involved the introduction of a weakened virus into the body to form a subsequent immune response. Moderna (MRNA) and Pfizer (PFE) vaccines, created on the basis of informational RNA, work differently: they ”teach" human cells to produce a protein that triggers an immune response to prevent infection with coronavirus. Thus, the immune system of a vaccinated person is trained to recognize a protein containing Covid-19 and produce antibodies to it.As part of the conference, Pfizer announced the conclusion of three agreements with smaller industry players to accelerate RNA developments. The company sees a huge potential for RNA-based drugs - in particular, in the treatment of cancer and rare diseases. Amgen's interest in collaborating with Arrakis Therapeutics in the study of RNA is widely discussed, which could result in an order for several billion dollars for the latter. Pharmaceutical giants Johnson & Johnson (JNJ) and Eli Lilly (LLY) have so far limited themselves to restrained statements that they are exploring the possibilities of RNA technologies.Coronavirus pushes for partnerships instead of mergersFor the second year in a row, the healthcare sector has not heard about major deals. The coronavirus has shuffled all the cards. Previously, when a breakthrough technology was discovered, a pioneer was usually expected to be absorbed at a premium to the market, but the pandemic has taught companies to think in a new way, and now they are increasingly inclined to partnerships.The most telling example was the collaboration in the development of a coronavirus vaccine between Pfizer and BioNTech (BNTX). Through partnership, large players actually place an order for development to specialized companies with lower turnover. As a result, both sides benefit: pharmaceutical giants save money, and their partners receive orders and financing.Covid-19 ComebackHaving not had time to fully vaccinate against Covid-19, humanity faced a threat in the form of a new and more contagious variant of the coronavirus - "omicron". A strain from South Africa sets anti-records for morbidity in developed countries, involving pharmaceutical giants in a new development race.Some companies at the conference reported on the supply of their drugs against coronavirus. So, Moderna reported that its sales in 2021 amounted to $ 18.5 billion. GlaxoSmithKline (GSK), in partnership with Vir Biotechnology (VIR), reported on the supply to the US government of 600 thousand doses of the drug for the treatment of Covid-19 sotrivimab. Novavax (NVAX) announced that it has already made the first shipments to Europe of its Covid-19 vaccine, but did not specify the volume of orders. And Gilead Sciences (GILD) has informed that its drug remdesivir may soon be approved by the US regulator for the treatment of coronavirus.As for the development of drugs aimed directly against the omicron strain, only Regeneron (REGN) and Pfizer have made statements about this. Regeneron is going to test the treatment of omicron with antibodies in the first quarter, and Pfizer spoke about the progress in creating a new vaccine against Covid-19, which will also work against the new strain.There is an opinion that omicron as an opportunity rather than a threat. Perhaps omicron is our salvation from coronavirus restrictions, since the body of vaccinated people, having met with a new strain of virus from South Africa, gives an immune response, which can be considered as an alternative to booster vaccination. Which, in a global effect, can give massive protection against coronavirus infection.Patent diversificationLarge pharmaceutical companies are in a hurry to reassure investors who are beginning to pay attention to the patent terms of drugs that occupy a large share in their sales.As a rule, after the expiration of a patent for a particular drug, the market is flooded with its cheaper copies, which significantly reduces the revenue of the manufacturer of the original drug. Therefore, investors expect a diversified portfolio of developments from pharmaceutical giants, which will include not only expensive cancer drugs, but also a wide range of medicines for other diseases.For example, the patent of the anti-cancer drug from Merck & Co (MRK) Keytruda expires in 2028. Total sales of this drug for 2020 amounted to $14.4 billion, which accounted for 30% of Merck's revenue. If the company does not explain to investors before the expiration of the exclusivity period how it is going to compensate for the upcoming "loss” of sales volumes, the market reaction can be very negative.Analysts' opinionAn endless "arms race" continues in the pharmaceutical sector. Since breakthrough technologies and patents provide only a temporary competitive advantage, companies have to constantly set themselves new and new goals.However, the JPMorgan conference reflected some changes in the behavior of both pharmaceutical companies and their investors. Industry representatives confirmed their propensity to create partnerships, and investors confirmed their demands for diversification of development portfolios.The most obvious new trend among the elite of pharmacology has been the use of ribonucleic acid to encode the human immune system. It is assumed that with the proper development of technology, scientists will be able not only to achieve the necessary immune response to various infectious diseases, but also to eliminate defects in hormones or blood quality.And the main intrigue remains who will be the first to develop a vaccine against the omicron strain. Leading pharmaceutical giants are studying its characteristics, causes of origin and the reaction of previously vaccinated people to it. Thus, the beginning of this year is similar to the beginning of the previous one. Back then, we were also on the verge of creating a working version of the vaccine and watched the deadly virus walk around the planet ...
Read
About the trends of 2022
Litecoin/USD, cryptocurrency, Ethereum/USD, cryptocurrency, Bitcoin/USD, cryptocurrency, Pfizer, stock, Moderna, stock, About the trends of 2022 A couple of steps away from the new year, many are trying to predict the direction of market winds over the next year, and maybe several. We have also analyzed promising ideas of stock exchanges, and today we will share them with you. In general, everything promising in the coming year is connected with the healthcare sector. Next, let's talk about the two most promising companies in this segment.NovavaxNovavax company was one of the first to enter the championship in the development and creation of a vaccine, but in this case it is still far from the podium. Does the company have real prospects? Let's talk about this further.At the beginning of the year, many experts argued that it was simply not advisable to get involved in the company's struggle. This was due to the fact that there were already many manufacturers of similar drugs, and there was not enough space for new ones. As a result, the experts' "verdict" turned out to be reckless, and today many are confident that the company's assets are among the most attractive in the coming year.The vaccine was one of the first to be released in Europe. It is based on a protein, which in the future can become an alternative for patients who refuse to be vaccinated by Pfizer and Moderna, developed on the basis of RNA.In the spring of 2021, she presented the results of testing a new vaccine to the world, and in mid-summer, repeated tests were conducted in America. The effectiveness of the drug according to the test results ranges from 89.7% to 90.4%. This high indicator allowed the drug to get into the top three most effective, and the company to become a leader in the world market of manufacturers.Immediately after the publication of the results, it was expected that the company's assets should increase in value, but problems with bureaucratic hitches and permission to use the vaccine on world markets led to the fact that the share price remained in place, and subsequently even declined.Different sources explain this fall in different ways. Some argue that there are no special technological lines for the production of the drug in the United States. Others are sure that the drug simply does not meet the standards established in the state, contains unnecessary impurities that can cause a lot of side effects.Today, the drug is recognized in several countries of the world, including Indonesia, India. The vaccine has the permission of the WHO and the euroregulator, together with the submission of the application, it has received permission in several other countries.Today Novavax is awaiting regulatory approval in many countries around the world, including Australia, Canada, South Korea, and the United Kingdom. To accelerate the production of the drug, the company is sponsored by a number of large-scale organizations, including the Gates Foundation and even the American government.If new strains of coronavirus continue to appear, the disease will be transferred to the category of endemic. That is why vaccination will very soon become a routine procedure, and it is also likely that the demand for combined drugs will grow, which the company is currently testing.It is not enough to be able to treat well, you also need to correctly diagnose diseases. That is why next we will talk about the manufacturer of medical equipment for diagnostics.Thermo Fisher ScientificThermo Fisher Scientific is geographically located in Massachusetts. It is one of the leaders in the production of diagnostic tools and equipment used in laboratory and outpatient settings, as well as consumables. The production of coronavirus vaccines and medicines for this pathology is considered to be an equally significant area of activity of the enterprise. From the beginning of the pandemic to the present time, the demand for the company's products remains at a height, so the company today occupies a leading position in the field of medicine.In the spring of 2021, the International Health Association granted the company a license to produce SARS-CoV-2, a test for detecting covid-19. The volume of revenue received only from anti-weed products today has already amounted to $2.05 billion. With the emergence of new strains of coronavirus, the demand for the company's products will only grow.The TMO quarterly report, released on October 27, turned out to be quite strong. Revenue exceeded last year's figure by 15%, as well as by $ 1.2 billion in monetary terms. In total, it amounted to 37.1 billion dollars. According to forecasts, the amount of revenue will increase by $1 billion, and will amount to $7.7 billion.The forecast for this indicator was $40.5 billion, which shows the excellent position of the enterprise, especially for modern market realities. The growth of the company's asset price index exceeded the S&P 500, and reached 40%. With great probability, we can say that the group's positions will continue to be stable.Another trend of the century is electric carsThe vast majority of major analysts last year warned against acquiring Nio assets. At that moment, no one could have thought that the company's market capitalization could reach $90 billion. The volume of cars produced at the same time is 20 thousand units annually.However, over the past year, the company has managed to become an industry leader, and excellent financial results are expected in 2022. This is despite supply disruptions and other problems associated with the pandemic. The company has several new products that will help it increase its market share in China, and take a strong position on it.In the autumn of 2021, the number of cars produced by the company reached 10,900 units, which indicates an active growth in demand for cars with an engine capacity of more than 130,000 per year. The company is going to release about 600 thousand units of cars by the end of 2022. Nio's management plans to introduce three new electric cars to the world market. If the sales growth of cars remains at the planned indicators, then Nio may well have the opportunity to bypass Tesla by this parameter. At least in the Chinese market.An important advantage of the enterprise is the already launched Battery-as-a-service or BaaS program. It allows you to make a monthly payment, which allows you to change the battery on an electric car in the future or update the battery charge. It will also be possible to buy a car without a battery, rearranging it from old equipment.This system will allow the company to receive high-margin revenue in the long term. In addition, we should expect an increase in customer loyalty to the products. The company's assets showed a 13% growth in 2020, but during 2021 they managed to fall by 44%. Today they are stable at around $30. We are waiting for strong growth.Basic Attention TokenIt is already impossible to imagine the financial world without cryptocurrency. How to choose correctly between all the options – Bitcoin, Litecoin, Ethereum and others, and not be left out? An interesting option is offered by the Basic Attention Token.Over the past six months, investors' attention has been focused on tokens supporting the application. If we take into account that since the beginning of the year, the growth of bitcoin has approached 73%, then this is a minuscule compared to the start of the Siba-anu meme token, which soared to 47000000%. However, the main investment flow today is considered to be directed to a cryptocurrency that provides support for applications.In the large list of tokens, the Basic Attention Token from Brave Software deserves special attention. In particular, the token is especially attractive for investing for a long period. The company is now managed by B. Eich is the founder of Mozilla and JavaScript.Coins are mined using the Brave browser, where they are obtained by viewing advertising content. The web browser provides a high degree of security due to the built-in ad blocker and functions to block the collection of user data. Allows you to personally view ads released by program partners, as well as earn tokens by viewing it.Throughout December, bears dominated the cryptocurrency market, which negatively affected the VAT. As a result, the price of the token fell by 30% from the historical highs seen at the end of autumn. However, Bravo is confident that the price will recover its indicators very ...
Read
Message sent successfully.
We will contact you soon!